Amgen’s Mvasi Set For Blockbuster Status With 50% Share In US
Annualized Biosimilars Sales Tracking North Of $2bn On Bevacizumab Boom
Amgen’s biosimilars sales will almost certainly smash through the $2bn barrier in 2021, driven by the strength of its product portfolio including bevacizumab and trastuzumab. The California-based biotech has warned, however, that greater competition will naturally lead to pricing challenges.
You may also be interested in...
Japan’s Sawai was cautioned by one analyst earlier this year that it lacked sufficient excess production capacity to handle the sharp expansion in demand for its products. Now the company has announced plans to build a new solid dosage form facility.
Prescribers must better understand how biosimilars work and why they are safe to use, in order to ensure continued biosimilar uptake, Samsung Bioepis believes.
Biocon is still awaiting a site inspection as pandemic-related delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes it can still make good and garner market share. All eyes are also on traction for its insulin glargine via increased share of formulary contracts.